Semaglutide medication interactions: what you need to decide before starting

How slowed gastric emptying creates an absorption problem

The main mechanism behind semaglutide's interaction profile is one the drug is famous for: it slows the rate at which food and liquid leave the stomach. That effect is useful for appetite control. It is less helpful for oral medicines that rely on a predictable transit time through the gut to reach their target blood level.

The practical consequence is that medicines with a narrow therapeutic window (where too little or too much has real clinical consequences) deserve closer attention when semaglutide is added. Oral anticoagulants such as warfarin are a textbook example: if the drug is absorbed more slowly, INR monitoring becomes more important, especially in the first weeks of treatment. Your prescriber or anticoagulation clinic should know you are starting semaglutide.

Over-the-counter painkillers and the vast majority of common medicines are not meaningfully affected in most people. But the principle is worth understanding, because it explains why your prescriber asks about everything on your repeat prescription, not just the high-risk items. The interaction is pharmacokinetic rather than pharmacodynamic, meaning the issue is timing and absorption rather than one drug directly fighting another. For a fuller picture of how these effects play out in practice, the Wegovy medication interactions page goes into more clinical detail.

Blood-sugar medicines and the hypoglycaemia calculation

If you already take insulin or a sulfonylurea such as glibenclamide or gliclazide for type 2 diabetes, the interaction with semaglutide is predictable and manageable, but it does need to be managed. Semaglutide lowers blood glucose in its own right. Add that to a medicine that already drives insulin secretion or delivery, and the combined effect can push blood sugar too low.

This is not a reason to avoid semaglutide if you have type 2 diabetes; it is a reason for your prescriber to reduce the dose of the existing diabetes medicine before or shortly after starting. The BNF notes this explicitly, and the SmPC recommends monitoring. People on metformin alone face a much lower risk, because metformin does not independently trigger insulin release in a way that compounds hypoglycaemia.

Signs of low blood sugar (shakiness, sweating, confusion, feeling suddenly very hungry) should prompt testing and treatment with fast-acting glucose. If you are on insulin or a sulfonylurea and considering semaglutide, bring both medicine names to your consultation. A prescriber who can see the full picture of semaglutide alongside other medications will adjust the plan accordingly before dispensing anything.

Oral contraceptives: the absorption question for women starting treatment

This is the interaction question our prescribers hear most regularly. Semaglutide can reduce the peak concentration and slow the absorption of the combined oral contraceptive pill, because the pill is an oral medicine subject to the same gastric-emptying effect described above. The clinical implication is modest but real: contraceptive reliability may be reduced, particularly in the first weeks.

The NHS guidance referenced in the NHS England weight management injections guidance advises that women using the pill consider adding a non-oral contraceptive method during the initial period of treatment. Condoms are the straightforward backup. This is distinct from the tirzepatide guidance, which specifies a 4-week window for each dose increase; the semaglutide evidence is less precise about the duration, making it sensible to discuss personally rather than follow a fixed rule. Some women prefer to switch to a patch or intrauterine device while on treatment, entirely reasonable, and worth raising with your GP or our prescribers.

On a related note, semaglutide is not recommended during pregnancy, while breastfeeding, or for anyone actively trying to conceive. Those restrictions apply regardless of any interaction question. You can read more about what the treatment landscape looks like for women in these situations on the Wegovy overview page.

Less common but worth flagging: thyroid history, pancreatitis and alcohol

A personal or family history of medullary thyroid carcinoma, or a condition called multiple endocrine neoplasia type 2, means semaglutide is contraindicated. This is not an interaction in the classic drug-drug sense, but it functions like one in clinical screening: your prescriber is looking for this history before prescribing, and it would be flagged at consultation. If you are exploring your options and wondering whether OTC semaglutide is available without a prescription, that page explains the current regulatory position clearly.

A history of pancreatitis warrants a careful conversation too. The MHRA Drug Safety Updates index includes guidance on GLP-1 medicines and pancreatitis risk; the short version is that acute pancreatitis is an uncommon but documented side effect, and a pre-existing history changes the risk calculation. Severe, persistent stomach pain that seems to travel towards your back is always a reason to stop the medicine and get medical help promptly.

Alcohol is worth a brief mention. Heavy alcohol use increases the risk of pancreatitis independently, so the combination with semaglutide is something to mention honestly in your consultation. Occasional social drinking is a different matter and generally not a contraindication. If you want a comprehensive list of drugs to flag with your prescriber, the page covering what medications interact with Wegovy is a useful reference before your appointment. If you are thinking about the broader cost and process of getting started, the Wegovy cost page covers what private treatment includes. When you are ready to talk through your specific medication list with a prescriber, check your eligibility and the team will review everything the same day.